Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Building Capacity to Reduce Stroke in Children With Sickle Cell Anemia in the Dominican Republic: The SACRED Trial
source: Blood Advances
year: 2018
authors: Luisanna M. Sánchez, Rosa M. Nieves, Teresa Latham, Susan Stuber, Judy R. Luden, Gabriela S. Urcuyo, Melissa E. Berges, Carla Florencio, Carla Gonzalez, Paola Del Villar, Adam Lane, William Schultz, Neelum Jeste, Rafael Mena, Russell E. Ware
summary/abstract:The prevalence of sickle cell anemia (SCA) in the Dominican Republic is approximately 4 times that in the United States.
In the pediatric sickle cell clinic at Hospital Infantil Dr. Robert Reid Cabral (HIRRC) located in the capital city of Santo Domingo, Dominican Republic, 5% to 10% of children with HbSS (homozygous for hemoglobin S) develop primary stroke, with substantial morbidity and mortality.
Transcranial Doppler (TCD) ultrasonography has been shown to effectively identify the risk for primary stroke in the United States but is not routinely accessible or available in the Dominican Republic.
Hydroxyurea is a potent disease-modifying therapy for SCA that can reduce TCD velocities and prevent conversion of conditional to abnormal velocities. Hydroxyurea is available in the Dominican Republic, but health care providers do not have experience with dosing, and most families cannot afford the cost.
organization: Cincinnati Children's Hospital Medical Center, USA; Hospital Infantil Dr. Robert Reid Cabral, Dominican Republic; Centro de Obstetricia y Ginecología, Dominican RepublicDOI: 10.1182/bloodadvances.2018GS110818.
read more
Related Content
-
Fighting Through Our Pain TV With Thomas J. Harrington MDhttps://www.youtube.com/watch?time_conti...
-
Ischemic Stroke in Children and Young Adults with Sickle Cell Disease (SCD) in the Post-STOP EraBackground: The Stroke Prevention Trial ...
-
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
-
Patient Reported Outcomes and Adherence to Hydroxyurea in Adolescents and Young Adults With Sickle Cell Disease: A F...Background: SCD-related complications r...
-
Developing Hydroxyurea, the First FDA-Approved Therapy for Sickle Cell Diseasehttps://www.youtube.com/watch?v=0kIz5ZKy...
-
Siklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now availab...Medunik USA, a company dedicated to impr...
-
Teen with sickle cell disease takes class trip to Europe with Loyola Medicine’s helpAnyah Randolph, a teenager with sickle c...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.